扶正消瘀方联合常规西医治疗前列腺增生术后湿热瘀毒型前列腺癌的临床研究  

Clinical effect of Fuzheng Xiaoyu Formula combined with conventional medical for prostate cancer after hyperplasia resection of damp-heat-stasis-toxin type

作　　者：赵杉[1] 黄浩然 王如然[1] 张玉杰[1] 陈明国[1] 李宏燕[1] 许华颖[1] ZHAO Shan;HUANG Haoran;WANG Ruran;ZHANG Yujie;CHEN Mingguo;LI Hongyan;XU Huaying(Department of Surgery,South District,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 102618)

机构地区：[1]中国中医科学院广安门医院南区外科,北京102618

出　　处：《河北中医》2022年第11期1790-1794,共5页Hebei Journal of Traditional Chinese Medicine

基　　金：中国中医科学院广安门医院南区科研基金课题(编号:YA2018-10)。

摘　　要：目的 观察扶正消瘀方联合常规西医治疗前列腺增生术后湿热瘀毒型前列腺癌(PCa)的临床疗效。方法 将96例前列腺增生术后湿热瘀毒型PCa患者按照随机数字表法分为2组,对照组48例予西医常规治疗,治疗组48例在对照组治疗基础上予扶正消瘀方治疗。2组均治疗12周。比较2组治疗前后国际前列腺症状评分(IPSS)、血清前列腺特异性抗原(PSA)、白细胞介素10(IL-10)、IL-6水平及治疗后前列腺癌患者生存质量测定量表(FACT-P)评分,比较2组疗效和5年内中位生存时间,并对治疗组中医治疗与其他指标进行相关性分析。结果 治疗组总有效率93.75%(45/48),对照组总有效率81.25%(39/48),治疗组疗效优于对照组(P<0.05)。2组治疗后IPSS均较本组治疗前降低(P<0.05),且治疗组治疗后低于对照组(P<0.05)。2组治疗后血清PSA、IL-10、IL-6水平均较本组治疗前降低(P<0.05),且治疗组治疗后均低于对照组(P<0.05)。2组治疗后FACT-P量表各项评分均较本组治疗前升高(P<0.05),且治疗组治疗后FACT-P量表各项评分均高于对照组(P<0.05)。治疗组中位生存期高于对照组(P<0.05)。经Pearson分析发现,中医治疗与临床分期、年龄、症状评分无关,但与生存率、生活质量有一定相关性(P<0.05)。结论 扶正消瘀方联合常规西医治疗前列腺增生术后湿热瘀毒型PCa患者能促进缓解临床症状,抑制PSA、IL-10、IL-6的释放,从而提高治疗效果,延长患者的生存时间。Objective To observe the clinical effect of Fuzheng Xiaoyu Formula combined with conventional medicine for prostate cancer(PCa) after benign prostatic hyperplasia resection of damp-heat-stasis-toxin type. Methods Totally 96 patients with PCa after benign prostatic hyperplasia resection(damp-heat-stasis-toxin type) were randomly assigned into the treatment group and the control group with 48 per group. The treatment group was treated with Fuzheng Xiaoyu Formula combined with conventional Western medicine, the control group with conventional medicine only. Treated for 12 weeks, aiming to compare international prostate symptoms score(IPSS), prostate specific antigen(PSA), interleukin-10(IL-10), interleukin-6(IL-6), Functional Assessment of Cancer Therapy-Prostate(FACT-P), curative effect, median survival;and the correlation between TCM treatment and other indicators was analyzed. Results The overall effective rate was 93.75%(45/48) in the treatment group, higher than that of 81.25%(39/48) in the control group(P<0.05). After treatment, IPSS in groups was decreased(P<0.05), the treatment group was more common(P<0.05);PSA, IL-10, IL-6 in groups was decreased(P<0.05), the treatment group was more prevalent(P<0.05);FACT-P scores in the treatment group were increased as compared to the control group(P<0.05);the median survival was increased(P<0.05) in the treatment group relevant to the control group. Pearson analysis showed that TCM treatment was not correlated with clinical stage, age and symptom score, but with quality-of-life and survival rate(P<0.05). Conclusion For patients with PCa after benign prostatic hyperplasia(damp-heat-stasis-toxin), Fuzheng Xiaoyu Formula combined with conventional medicine can relieve clinical symptoms and inhibit the release of PSA, IL-10 and IL-6, thereby improving the therapeutic effect and prolonging the survival time.

关 键 词：前列腺肿瘤 湿热 前列腺特异抗原 中药疗法 

分 类 号：R737.250.531[医药卫生—肿瘤]